Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: A pilot study

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1177-1181

  Lorusso, Vito ^a   Catino, Annamaria ^a   Schittulli, Francesco ^a   Longo, Salvatore ^a   Racanelli, Angela ^a   Timurian, Artur ^a   Marzullo, Franco ^a   Simone, Giovanni ^a   Brandi, Mario ^a   De Lena, Mario ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Accelerated chemotherapy; Breast cancer; Granulocyte colony stimulating factor; Primary chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 13144255746     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1177     Document Type: Article

References (28)

1. Mansi J, Smith IE, Walsh G, et al: Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25: 1623-1627, 1989.
2. Bonadonna G II, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990.
3. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 553-559, 1995.
4. Goldie JH and Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923-931, 1983.
5. Goldie JH and Coldman A: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44: 3643-3653, 1984.
6. Simpson-Herren L, Sarrford AH, Holmquist JP, et al: Effects of surgery in the cell kinetics of residual tumor. Cancer Treat Rep 60: 1744-1760, 1976.
7. Fisher B II, Gunduz N and Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1482-1488, 1983.
8. Goldie JH: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14: 1-7, 1987.
9. De Lena M, Zucali R and Viganotti G, et al: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1: 53-59, 1978.
10. Swain SM, Sorace RA, Bagley CS, et al: Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer. Cancer Res 47: 3889-3894, 1987.
11. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62: 2507-2516, 1988.
12. Van de Velde C: Preoperative chemotherapy in operable breast cancer. The influence of timing FEC in relation to surgery. Drugs 45 (Suppl 2): 31-37, 1993.
13. Bronchud MH, Potter MR, Morgenstern G, et al: In vitro and in vivo analysis of the effects of recombinant human G-CSF in patients. Br J Cancer 58: 64-69, 1988.
14. Morstyn G, Souza LM, Keech J, et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet i: 667-672, 1988.
15. Morstyn G, Campbell L, Lieschke G, et al: Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7: 1554-1562, 1989.
16. Bronchud MH, Howell A, Crowther D, et al: The use of granulocyte colony stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60: 121-125, 1989.
17. Lorusso V, Berardi F, Tatulli G, et al: Accelerated chemotherapy with mitoxantrone plus G-CSF in heavily pretreated patients with metastatic breast cancer. Oncol Rep 1: 591-595, 1994.
18. WHO: Handbook for Reporting Results of Cancer Treatment. Geneva, 1979.
19. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127-2137, 1992.
20. Goldie JH and Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733, 1979.
21. Skipper HE and Shabel FM Jr: Tumor stem cell heterogeneity: implication with respect to the classification of cancers by chemotherapeutic effect. Cancer Treat Rev 68: 43-61, 1984.
22. Fisher B and Mamounas E: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537-540, 1995.
23. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995.
24. Bonadonna G, Valagussa P, Brambilla C, et al: Preoperative chemotherapy in operable breast cancer (letter to editor). Lancet 341: 1485, 1993.
25. Bonadonna G: From adjuvant to neoadjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992. Int J Cancer 55: 1-4, 1993.
26. Bennet JM, Müss HB, Doroshow JH, et al: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611-1620, 1988.
27. Periti P, Pannuti F, Robustelli della Cuna G, et al: Combination chemotherapy with cyclophosphamide, fluorouracil and either epirubicin or mitoxantrone. A comparative randomized multicenter study in metastatic breast cancer. Cancer Insert 9: 249-255, 1991.
28. Lorusso V, Catino A, Brandi M, et al: Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophoshamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. Int J Oncol 4: 767-772, 1994.